Genedx Holdings Corp. · NASDAQ:WGS
Genedx — 42nd Annual JPMorgan Healthcare Conference (January 2024)
23 slides from Genedx's conference presentation, Jan 8, 2024
Slide 1: One test. Big picture. Brighter futures.
One test. Big picture. Brighter futures. GeneDx (Nasdaq: WGS) Katherine Stueland, President and Chief Executive Officer 42nd Annual JPMorgan Healthcare Conference January 8, 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for
Slide 3: 4Q 2023 preliminary results
4Q 2023 preliminary results 1 Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from 2 continuing operations expected to be least $57M with 63% year-over-year revenue growth for exome and genome test revenue Reduced cash burn 51% year-over-year and 21% sequentially End
Slide 4: Preliminary Revenue - strong growth driven by high value whole exome and genome
Preliminary Revenue - strong growth driven by high value whole exome and genome Revenue 1 Q4 2023 Increase in exome/genome test result Revenue from continuing operations At least $57M 99% volume year-over-year; +19% sequentially Growth year-over-year 24% Growth sequentially 13% Exome/genome test res
Slide 5: Preliminary Cash - Balance sheet bolstered to execute growth strategy
Preliminary Cash - Balance sheet bolstered to execute growth strategy Net use of cash 1 Q4 2023 Consecutive quarters of cash burn 7 reduction since acquiring GeneDx Total company $33M Continuing operations $24M 1 Total Company use of cash in the fourth quarter included $5 million in scheduled paymen
Slide 6: Our path to profitability and beyond
For illustrative purposes, Confidential not formal and Proprietary; guidance Do Not Distribute Our path to profitability and beyond What we need for profitability and beyond How we will achieve those goals ▪ On October 30, 2023, we enacted a plan to remove OPEX reduction approximately $40M in annual
Slide 7: Lack of genomic data can lead to a cycle of misdiagnosis and suboptimal care
Lack of genomic data can lead to a cycle of misdiagnosis and suboptimal care Patient Missed diagnoses impact everyone presents with Tests are More symptoms ordered spending Patients/Caregivers • Inappropriate treatments and delayed care • Suffering Try new Suboptimal doctors Healthcare systems care
Slide 8: Genomic information is the most foundational health data source
Genomic information is the most foundational health data source Each person's unique genetic code influences their health – and fundamentally informs how we use other data tools. 8
Slide 9: Exome and genome testing unlock the most comprehensive genomic data
Exome and genome testing unlock the most comprehensive genomic data As a leader in exome and genome testing, GeneDx leverages the power of this data to: o Inform personalized health plans o accelerate drug discovery o improve efficiencies for health systems o enable healthier populations 9
Slide 10: GeneDx is positioned to enable a data-informed future for healthcare.
GeneDx is positioned to enable a data-informed future for healthcare.
Slide 11: Leading exome and genome products
Leading exome and genome products Translating complex genomic data into definitive diagnoses for patients o For more than 20 years, our advanced genomic technologies and unparalleled data have helped diagnose the hardest cases. o Now we’re helping patients with more common conditions harness the pow
Slide 12: Common diseases are in fact a constellation of genetic diagnoses
Common diseases are in fact a constellation of genetic diagnoses One example is epilepsy. At least 768 different genes are related to seizures. Only 43% are tested on many commercial epilepsy panels 12 Butler L. et al. Exome-based testing for patients with seizures: Advantages over panel-based testi
Slide 13: Common diseases are in fact a constellation of genetic diagnoses
Common diseases are in fact a constellation of genetic diagnoses One example is epilepsy. At least 768 different genes are related to seizures. Only 43% are tested on many commercial epilepsy panels Exome sequencing checks all 768 genes 13 Butler L. et al. Exome-based testing for patients with seizu
Slide 14: Data is at the center of our business
Data is at the center of our business Our huge dataset and intelligent interpretation platform set us apart and fuel innovation Advanced interpretation platform Simplifies complex genomic data 500K sequenced exomes Significant clinical and Reduces variants of genomic data unknown significance Fuels
Slide 15: Pay-it-forward data strategy
dditional dditional More answ ers patients patients for patients tested providers tested Pay-it-forward mproved igher interpretation data strategy diagnostic yield platform fewer S For every patient that we test, our More underlying interpretation platform answ ers for patients gets smarter, and we
Slide 16: Snowball effect of our ever-growing dataset
Snowball effect of our ever-growing dataset Accumulated GeneDx data offers more findings and drives forward scientific discoveries Lab A GeneDx
Slide 17: Exome and genome can be the best tests for patients. They're also the best tests for our business.
Exome and genome can be the best tests for patients. They're also the best tests for our business.
Slide 18: Today, we shorten the diagnostic journey. Tomorrow, we hope to prevent it.
Today, we shorten the diagnostic journey. Tomorrow, we hope to prevent it.
Slide 19: Building the future: NICU
Building the future: NICU Shorter hospital stays. Less uncertainty. Better care. In phase one of the SeqFirst study, 125 infants were offered rapid WGS: 63% of infants had abnormal rapid WGS results, and 88% of these cases resulted in a change in management 1 in 4 infants with abnormal results were
Slide 20: Building the future: Newborn screening
Building the future: Newborn screening Fast diagnosis. Clear next steps. Reduced healthcare costs. Screened 5,000 healthy infants, toward goal of >100,000 4.3% positive rate Average age of diagnosis for these conditions is 7-11 years old 20
Slide 21: Building the future: Partnerships
Building the future: Partnerships Enriched data. Empowered drug discovery. mproved outcomes. GeneDx offers solutions across the pharma drug development pipeline Find Connect Understand 21
Slide 22: Building the future: Interpretation as a service
Building the future: Interpretation as a service Scientific rigor. Medical value. Establishing genomics as the standard of care for all. 22
Slide 23: All paths lead to
The right organization. In the right space. At the right time. All paths lead to 23
GeneDx Holdings — 42nd Annual JPMorgan Healthcare Conference (January 2024) on 6ix